000121076 001__ 121076
000121076 005__ 20230519145530.0
000121076 0247_ $$2doi$$a10.1097/WNO.0000000000000991
000121076 0248_ $$2sideral$$a126987
000121076 037__ $$aART-2021-126987
000121076 041__ $$aeng
000121076 100__ $$0(orcid)0000-0001-6258-2489$$aGarcia-Martin E.$$uUniversidad de Zaragoza
000121076 245__ $$aProgressive functional and neuroretinal affectation in patients with multiple sclerosis treated with fingolimod
000121076 260__ $$c2021
000121076 5060_ $$aAccess copy available to the general public$$fUnrestricted
000121076 5203_ $$aBACKGROUND: To evaluate the effect of fingolimod in visual function and neuroretinal structures in patients with multiple sclerosis (MS) for a period of 1 year. METHODS: This longitudinal and observational cohort study included 78 eyes of 78 patients with MS treated with fingolimod. All subjects were evaluated every 3 months during 12 months and compared with 32 patients treated with interferon beta. All patients were examined for high-contrast and low-contrast (2.5% and 1.25%) visual acuity (VA), contrast sensitivity vision (CSV) (using Pelli-Robson and CSV-1000E tests), color vision (Farnsworth D-15 and L''Anthony D-15 desaturated tests), and retinal structural measurements (retinal nerve fiber layer [RNFL] and ganglion cell layer [GCL] thickness) using optical coherence tomography (OCT) technology. RESULTS: Patients with MS treated with fingolimod for a period of 1 year showed significant reduction in 100% and 1.25% contrast VA (P = 0.009 and 0.008, respectively), an alteration of contrast sensitivity and color perception (Pelli-Robson test, CSV-1000E test, Farnsworth D-15 desaturated test, and L''Anthony D-15 desaturated test; P < 0.001), GCL thickness reduction (P = 0.007), and an average macular central thickness increase of 2.6 µm (P = 0.006). Patients with MS treated with interferon beta did not show significant changes in visual function tests neither in macular thickness measurements, but they showed a significant reduction in GCL and RNFL thicknesses. The reduction in neuroretinal structures observed by OCT was significantly higher in the interferon-beta group, but patients treated with fingolimod showed a significant increase in macular central thickness and a reduction in low contrast vision (P < 0.001). CONCLUSIONS: Patients with MS treated with fingolimod and with no clinically observable macular edema show a significant change in visual function parameters and average macular central thickness increase compared with those treated with interferon beta. These findings are probably due to subclinical macular edema produced by fingolimod, which might be considered as an indicator for pharmacovigilance of sphingosine-1-phosphate inhibitors to be improved. Copyright © 2020 by North American Neuro-Ophthalmology Society.
000121076 536__ $$9info:eu-repo/grantAgreement/ES/MINECO-AEI-FEDER/MAT2017-83858-C2-2
000121076 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000121076 590__ $$a4.415$$b2021
000121076 591__ $$aOPHTHALMOLOGY$$b13 / 62 = 0.21$$c2021$$dQ1$$eT1
000121076 591__ $$aCLINICAL NEUROLOGY$$b75 / 212 = 0.354$$c2021$$dQ2$$eT2
000121076 592__ $$a0.731$$b2021
000121076 593__ $$aNeurology (clinical)$$c2021$$dQ2
000121076 593__ $$aMedicine (miscellaneous)$$c2021$$dQ2
000121076 594__ $$a2.3$$b2021
000121076 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000121076 700__ $$aRuiz de Gopegui E.
000121076 700__ $$0(orcid)0000-0002-1609-5994$$aSatue M.$$uUniversidad de Zaragoza
000121076 700__ $$aGil-Arribas L.
000121076 700__ $$aJarauta L.
000121076 700__ $$aAra J.R.
000121076 700__ $$aMartin J.
000121076 700__ $$aFernandez F.J.
000121076 700__ $$0(orcid)0000-0001-9411-5834$$aVilades E.$$uUniversidad de Zaragoza
000121076 700__ $$aRodrigo M.J.
000121076 7102_ $$11013$$2646$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Oftalmología
000121076 773__ $$g41, 4 (2021), e415-e423$$pJ. neuro-ophthalmol.$$tJournal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society$$x1070-8022
000121076 8564_ $$s384948$$uhttps://zaguan.unizar.es/record/121076/files/texto_completo.pdf$$yPostprint
000121076 8564_ $$s1190314$$uhttps://zaguan.unizar.es/record/121076/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000121076 909CO $$ooai:zaguan.unizar.es:121076$$particulos$$pdriver
000121076 951__ $$a2023-05-18-15:29:36
000121076 980__ $$aARTICLE